PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE
February 14, 2001
Intramuscular Olanzapine (NDA 21-253) for the Rapid Control of Agitation, Eli Lilly and Company
The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Slides ppt html
Additional Slides ppt html